- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Provider Acceptance Driving Confidence in Biosimilar Therapy
Providers speak to the importance of being knowledgeable of efficacy and safety data before prescribing biosimilars to patients.
EP: 1.Utilizing Recently Approved Biosimilars in Clinical Practice
EP: 2.Transitioning to Biosimilars: Considerations for Providers and Payers
EP: 3.Navigating Challenges Associated with Biosimilars Across Various Disease States
EP: 4.Provider Acceptance Driving Confidence in Biosimilar Therapy
EP: 5.Decision-Making Process Surrounding Biosimilar Implementation
EP: 6.Biosimilar Administration Considerations Impacting Patient Experience
EP: 7.Initiating Biosimilar Treatment in Patients Without Previous Reference Biologic Experience
EP: 8.Switching Patients from Reference Product to Biosimilar
EP: 9.Defining Interchangeability and Switching in Biologics
EP: 10.Evolution of Auto-Substitution in Biosimilar Landscape
EP: 11.An Overview of Biosimilar Extrapolation During FDA Approval
EP: 12.Harnessing Indication-Specific Data on Biosimilars
EP: 13.Cost Savings Related to Biosimilars
EP: 14.Payers and PBMs Impacted by Biosimilar Integration
EP: 15.Payer Support Driving Lowering of Biosimilar-Related Health Care Costs
EP: 16.Patient Conversations: Managing Patient Expectations Regarding Biosimilars
EP: 17.Key Points of Emphasis Regarding Biosimilar Integration
This is a video synopsis/summary of a panel discussion involving Ryan Haumschild, PharmD, MS, MBA; Alice B. Gottlieb, MD, PhD; Bincy Abraham, MD, MS; Jamie T. Brogan, APRN; and Vibeke Strand, MD.
Haumschild asked Abraham about the role of provider acceptance and confidence in biosimilars in driving adoption for inflammatory conditions.
Abraham said if a payer requires switching to a biosimilar, providers must comply regardless of confidence. However, provider knowledge of the biosimilar’s efficacy, safety, expected effects of switching, and so on allows confident counseling of patients concerned about changes in their medication for chronic disease. An informed provider can explain details to patients, reducing nocebo effects from anxiety about switching. Provider knowledge and confidence in biosimilars significantly helps adoption from the provider and patient standpoint.
Haumschild agreed that provider understanding of data enables confident prescribing and trust from patients, which has been crucial for biosimilar adoption. This transition of acceptance and confidence will be vital as inflammatory disease options expand.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
January 29th 2025In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Read More
Niraparib Extends PFS, Time to Next Treatment in Patients With EOC, Especially BRCA-Mutated Cases
January 28th 2025First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC), with the greatest benefit observed in those considered homologous recombination-deficient (HRd) and those with BRCA-mutated (BRCAm) tumors.
Read More
Historical Redlining Increases Mortality Risk Among Young Patients With Cancer
January 27th 2025Young patients with cancer residing in historically redlined areas face a significantly higher risk of mortality, demonstrating that structural racism contributes to disparities in survival outcomes.
Read More
